Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Overview of attention for article published in Blood, January 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 2 news outlets
twitter: 22 X users

patent: 5 patents
guideline: 2 clinical guideline sources

Readers on

mendeley: 181 Mendeley

So far, Altmetric has seen 5 patents that reference this research output.

PURIFYING TCR-MODIFIED T CELLS USING TCR-SPECIFIC CAR-NK CELLS

Application WO-2024079109-A1

World Intellectual Property Organisation (WIPO)

18 Apr 2024

PURIFICATION OF TCR-MODIFIED T CELLS USING TCR-SPECIFIC CAR-NK CELLS

Application EP-4353253-A1

European Patent Office

17 Apr 2024

GENETICALLY ENGINEERED ANTI-CD19 CAR-T CELLS FOR USE IN TREATING B-CELL MALIGNANCIES

Application US-20240115703-A1

United States of America

11 Apr 2024

CAR THERAPY RESPONSE PREDICTION

Application US-20240060965-A1

United States of America

22 Feb 2024

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 1 additional patents.